Isolation of Endogenous Anticoagulant N-Sulfated Glycosaminoglycans in Human Plasma from Healthy Subjects

Endogenous N-sulfated glycosaminoglycans (GAGs) comigrating with standard heparin and sensitive to nitrous acid treatment were isolated from plasma of healthy donors. The amount of these compounds was 7–10 µg/ml, and activated partial thromboplastin time, anti-Xa and anti-IIa activities were similar to those of standard heparin of high molecular mass. Analysis with gradient PAGE of the putative endogenous heparin showed a mean molecular mass of 12 kD. These N-sulfated GAGs could be isolated only after removal of binding peptides that impaired purification by ion-exchange chromatography. We used SDS-PAGE as a tool to separate peptides from endogenous GAGs. N-sulfated GAGs exited the gel before peptides when the electrophoresis was overrun. Endogenous GAGs could be recovered by ion-exchange chromatography of the SDS-PAGE buffer, ‘free’ from associating peptides. These results strongly support the hypothesis that endogenous heparin is associated in vitro with a variety of proteins and that this association could be responsible for modification of both heparin and protein activities.

[1]  M. Ruggiero,et al.  Heparin binding peptides co‐purify with glycosaminoglycans from human plasma , 1999, FEBS letters.

[2]  S. Cavari,et al.  Detection of heparin-like glycosaminoglycans in normal human plasma by polyacrylamide-gel electrophoresis. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[3]  P. Bianchini,et al.  Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. , 1995, Haemostasis.

[4]  J. Millet,et al.  The effect of the beta-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit. , 1995, The Journal of biological chemistry.

[5]  N. Volpi,et al.  Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. , 1995, Biochimica et biophysica acta.

[6]  R. Mulligan,et al.  Pathway-specific regulation of the synthesis of anticoagulantly active heparan sulfate. , 1994, The Journal of biological chemistry.

[7]  M. Masserini,et al.  Modifications of low density lipoprotein induced by the interaction with human plasma glycosaminoglycan-protein complexes. , 1994, Biochimica et biophysica acta.

[8]  S. Cavari,et al.  Glycosaminoglycans exposed on the endothelial cell surface , 1993, FEBS letters.

[9]  L. Stramaccia,et al.  Endogenous heparinase-sensitive anticoagulant activity in human plasma. , 1992, Thrombosis research.

[10]  A. Calatroni,et al.  Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behaviour of the protein-polysaccharide complexes in ultrafiltration and chromatographic procedures. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[11]  O. Wilson,et al.  A heparin-like anticoagulant as part of global abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma. , 1991, The Journal of laboratory and clinical medicine.

[12]  L. Magnelli,et al.  Interaction between endogenous circulating sulfated-glycosaminoglycans and plasma proteins. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[13]  M. Lyon,et al.  A general method for the detection and mapping of submicrogram quantities of glycosaminoglycan oligosaccharides on polyacrylamide gels by sequential staining with azure A and ammoniacal silver. , 1990, Analytical biochemistry.

[14]  T. Anastassiades,et al.  Electrophoresis of glycosaminoglycans isolated from normal human plasma. Direct evidence for the presence of a heparin-like molecule. , 1987, Biomedica biochimica acta.

[15]  I. Staprans,et al.  Isolation and characterization of glycosaminoglycans in human plasma. , 1985, The Journal of clinical investigation.

[16]  U. Abildgaard,et al.  Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin. , 1984, Thrombosis research.

[17]  H. Gralnick,et al.  Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. , 1984, The New England journal of medicine.

[18]  Denis R. Miller,et al.  A heparin‐like anticoagulant in an 8‐month‐old boy with acute monoblastic leukemia , 1984, American journal of hematology.

[19]  V. Chiarugi,et al.  Adhesion-dependent heparin production by platelets , 1982, Nature.

[20]  V. Chiarugi,et al.  A new method for characterization of N-sulfated glycosaminoglycans by a rapid and multisample nitrous acid treatment during an electrophoretic run and its application to the analysis of biological samples. , 1980, Analytical biochemistry.

[21]  R. Hata,et al.  Low-sulfated chondroitin sulfate in human blood and urine. , 1978, Biochimica et biophysica acta.

[22]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[23]  M. Lie,et al.  Assay of heparin in plasma using a chromogenic substrate for activated factor X. , 1976, Thrombosis research.

[24]  J. Hirsh,et al.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. , 1972, The New England journal of medicine.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.